Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/19/2009US20090076086 Substituted nicotinamide compounds and uses thereof
03/19/2009US20090076085 Deuterium-enriched nicraven
03/19/2009US20090076083 Deuterium-enriched saredutant
03/19/2009US20090076082 Deuterium-enriched alvimopan
03/19/2009US20090076081 Piperidine derivatives as nk3 antagonists
03/19/2009US20090076080 Deuterium-enriched fexofenadine
03/19/2009US20090076079 Deuterium-enriched methylphenidate
03/19/2009US20090076078 New compounds 966
03/19/2009US20090076077 Methods and Compositions for Selectin Inhibition
03/19/2009US20090076076 Inhibitors of cysteine proteases and methods of use thereof
03/19/2009US20090076075 Quinoline derivatives
03/19/2009US20090076074 Quinoline derivatives
03/19/2009US20090076073 Therapeutic amides
03/19/2009US20090076072 Deuterium-enriched tafenoquine
03/19/2009US20090076071 Deuterium-enriched retapamulin
03/19/2009US20090076070 Hetero compound
03/19/2009US20090076069 Deuterium-enriched apixaban
03/19/2009US20090076068 Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
03/19/2009US20090076067 Pharmaceutical composition comprising azarhodacyanine compound as active ingredient
03/19/2009US20090076066 Deuterium-enriched zolpidem
03/19/2009US20090076065 Deuterium-enriched mk-0812
03/19/2009US20090076064 Compounds
03/19/2009US20090076063 Carboxamide compound and use of the same
03/19/2009US20090076062 Organic Compounds
03/19/2009US20090076061 Muscarinic acetycholine receptor antagonists
03/19/2009US20090076060 Deuterium-enriched temsirolimus
03/19/2009US20090076059 Deuterium-enriched dianicline
03/19/2009US20090076058 Deuterium-enriched finasteride
03/19/2009US20090076057 Deuterium-enriched dutasteride
03/19/2009US20090076056 Deuterium-enriched topotecan
03/19/2009US20090076055 Deuterium-enriched vinflunine
03/19/2009US20090076054 lysate reagent is added into a sample in the presence of albumin and/or globulin; preparing an injection containing a camptothecin derivative, a timiperone or a taxane derivative and having an endotoxin concentration of less than a specification limit
03/19/2009US20090076053 Methods and compositions for treating pain
03/19/2009US20090076052 Deuterium-enriched nalmefene
03/19/2009US20090076051 Deuterium-enriched methylnaltrexone
03/19/2009US20090076050 Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer
03/19/2009US20090076049 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1
03/19/2009US20090076048 Deuterium-enriched xaliproden
03/19/2009US20090076046 Compounds modulating c-fms and/or c-kit activity and uses therefor
03/19/2009US20090076045 Non-nucleoside reverse transcriptase inhibitors
03/19/2009US20090076044 Vegfr inhibitors containing a zinc binding moiety
03/19/2009US20090076043 Deuterium-enriched alfuzosin
03/19/2009US20090076042 Deuterium-enriched erlotinib
03/19/2009US20090076041 Acyclic nucleoside derivatives
03/19/2009US20090076040 Deuterium-enriched valganciclovir
03/19/2009US20090076039 Deuterium-enriched valacyclovir
03/19/2009US20090076038 Deuterium-enriched entecavir
03/19/2009US20090076037 Bicyclic pyrimidine kinase inhibitors
03/19/2009US20090076036 Deuterium-enriched risperidone
03/19/2009US20090076035 Deuterium-enriched paliperidone
03/19/2009US20090076034 Deuterium-enriched bms-690514
03/19/2009US20090076033 Method for treating atherosclerosis employing an aP2 inhibitor and combination
03/19/2009US20090076032 Derivatives of 18Beta-Glycyrrhetinic Acid
03/19/2009US20090076031 Deuterium-enriched bortezomib
03/19/2009US20090076030 Piperazine compounds
03/19/2009US20090076029 Compounds and Methods for Treating Obesity
03/19/2009US20090076028 Deuterium-enriched itraconazole
03/19/2009US20090076027 Deuterium-enriched lurasidone
03/19/2009US20090076026 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects of dry-mouth and constipation; biphenyl carbamate derivatives; biphenyl-2-ylcarbamic acid 1-(3-(3-[3-(4-hydroxybenzylamino)propyl]-2-oxoimidazolidin-1-yl)propyl)piperidin-4-yl ester
03/19/2009US20090076025 Deuterium-enriched dasatinib
03/19/2009US20090076024 Episomal Fusion Gene
03/19/2009US20090076023 Local Anesthetic Methods and Kits
03/19/2009US20090076022 Tartrate salts of quinazoline based egfr inhibitors containing a zinc binding moiety
03/19/2009US20090076021 Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease
03/19/2009US20090076020 Cyclopropyl Amide Derivatives 978
03/19/2009US20090076019 Methods for treating neurological disorders or damage
03/19/2009US20090076018 Deuterium-enriched ranolazine
03/19/2009US20090076017 Deuterium-enriched trabectedin
03/19/2009US20090076016 Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases
03/19/2009US20090076015 Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring
03/19/2009US20090076014 For administration with food; bioavailability
03/19/2009US20090076013 Deuterium-enriched sitagliptin
03/19/2009US20090076012 Modulation of pathogenicity
03/19/2009US20090076011 Deuterium-enriched tirapazamine
03/19/2009US20090076010 Deuterium-enriched lamotrigine
03/19/2009US20090076009 Thiazole derivatives and their use as anti-tumour agents
03/19/2009US20090076008 Deuterium-enriched fosaprepitant
03/19/2009US20090076007 Deuterium-enriched aprepitant
03/19/2009US20090076006 Hsp90 inhibitors containing a zinc binding moiety
03/19/2009US20090076005 Kinase inhibitor compounds
03/19/2009US20090076004 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics
03/19/2009US20090076003 Phthalazine Derivatives with Angiogenesis Inhibiting Activity
03/19/2009US20090076002 Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
03/19/2009US20090076001 Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments
03/19/2009US20090076000 Deuterium-enriched mycophenolate mofetil
03/19/2009US20090075999 Oxygen linked pyrimidine derivatives
03/19/2009US20090075998 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
03/19/2009US20090075997 Deuterium-enriched satavaptan
03/19/2009US20090075996 Heterotetracyclic compounds as tpo mimetics
03/19/2009US20090075995 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
03/19/2009US20090075994 Deuterium-enriched radafaxine
03/19/2009US20090075993 N-[3-(1 -piperidinyl)propoxy]-pyridin-1-oxide-3-carboxamidine ; increasing vaso-relaxation of a vessel associated with endothelial cells
03/19/2009US20090075992 Pteridine Derivatives as Nitric Oxide Synthase Activators
03/19/2009US20090075991 Deuterium-enriched efavirenz
03/19/2009US20090075990 Aerosol Formulation for Inhalation Containing an Anticholinergic Agent
03/19/2009US20090075989 Non-steroidal progesterone receptor modulators
03/19/2009US20090075988 phosphodiesterase inhibitors such as 1-[3-(4-fluoro-phenyl-piperazin-1-yl]-6,7-dimethoxy-isoquinoline-4-carbonitrile, having improved solubility, metabolic stability and/or bioavailability, used for the treatment of neurodegenerative diseases, psychological disorders and drug addiction
03/19/2009US20090075987 Alkylacetylene substituted acyltryptophanols
03/19/2009US20090075986 Anti-inflammatory medicaments
03/19/2009US20090075985 Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease